TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07024784: A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

Sponsor: AbbVie · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 377 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$7,900,200

Rescue Site Savings

+$5,220,600

Unlock Full NCT07024784 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024784 Rescue Dossier →